Neoadjuvant capecitabine and docetaxel (plus trastuzumab): An effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 588-594

  Wildiers, H ^a   Neven, P ^a   Christiaens, M R ^a   Squifflet, P ^b   Amant, F ^a   Weltens, C ^a   Smeets, A ^a   van Limbergen, E ^a   Debrock, G ^c   Renard, V ^d   van Eenoo, L ^a   Wynendaele, W ^a,e   Paridaens, R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d AZ St Lucas ^*  (Belgium)

^e IMELDA HOSPITAL   (Belgium)

Author keywords

Capecitabine; Docetaxel; Inoperable breast cancer; Neoadjuvant; Trastuzumab

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH PERFORATION; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 79953873317     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq406     Document Type: Article

References (34)

1. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-1934.
2. Steger GG, Greil R, Jakesz R, et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer-first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24). Eur J Cancer 2009; 7(Suppl): 3 (Abstr 4BA).
3. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
4. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
5. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27: 2474-2481.
6. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-2756.
7. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
8. Seidman A, Brufsky A, Ansari RH, et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). J Clin Oncol 2009; 27(Suppl): 15s (Abstr 1000).
9. Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009; 27: 1753-1760.
10. Mavroudis D, Papakotoulas P, Ardavanis A et al., on behalf of the Breast Cancer Investigators of the Hellenic Oncology Research Group. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2010; 21: 48-54.
11. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of firstline trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 976-983.
12. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al., on behalf of the FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 2009; 10: 1145-1151.
13. Lee KS, Ro J, Nam BH, et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 2008; 109: 481-489.
14. Bellet M, Munõz M, Bellosillo B, et al. Phase II study of capecitabine (X) + docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates. J Clin Oncol 2006; 24(18S): 664.
15. Layman RM, Thomas DG, Griffith KA, et al. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 2007; 13: 4092-4097.
16. Tripathy D, Moisa C, Gluck S. Neoadjuvant capecitabine plus docetaxel 6 trastuzumab therapy for recently diagnosed breast cancer: phase II results. Breast Cancer Res Treat 2007; 106(Suppl 1): S226 (Abstr 5059).
17. Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004; 10: 6764-6769.
18. Jinno H, Sakata M, Hayashida T, et al. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 2010; 21: 1262-1266.
19. Natoli C, Cianchetti E, Tinari N, et al. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Ann Oncol 2007; 18: 1015-1020.
20. Chia S, Lohrisch G, Gelmon K, et al. Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel and capecitabine for HER2-negative locally advanced breast cancer (LABC): a multicenter study from British Columbia. J Clin Oncol 2009; 27(Suppl): 15s (Abstr 598).
21. Chollet P, Bougnoux P, Amat S, et al. Induction chemotherapy in operable breast cancer: high pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol 1999 (Abstr 297).
22. D'hondt R, Paridaens R, Wildiers H, et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2004; 15: 341-346.
23. ®) for patients with anthracycline pre-treated metastatic breast cancer. Proc Am Soc Clin Oncol 2002 (Abstr 1984).
24. Mackey JR, Tonkin KS, Koski SL, et al. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004; 5: 287-292.
25. Kim WE, Serrero G. PC cell-derived growth factor stimulates proliferation and confers trastuzumab resistance to Her-2-overexpressing breast cancer cells. Clin Cancer Res 2006; 12: 4192-4199.
26. Costa SD, Loibl S, Kaufmann M, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 2010; 28: 83-91.
27. Glück S, McKenna EF Jr, Royce M. XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci 2008; 5: 341-346.
28. Fernández-Morales LA, Seguí MA, Andreu X, et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer 2007; 7: 559-564.
29. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
30. Steger GG, Greil R, Jakesz R, et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res 2009; 69(Suppl): 564s (Abstr 1081).
31. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
32. von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28: 2015-2023.
33. Earl HM, Vallier A, Hiller L et al., for the NeotAnGo investigators. Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009; 15s: 522.
34. Wildiers H, Forceville K, Paridaens R, et al. Taxanes and anthracyclines in early breast cancer: which first? Lancet Oncol 2010; 11: 219-220.